ONETOUCH REVEAL® PLUS FOR HEALTH PLANS AND SYSTEMS

See What Digital Coaching Can Offer

OneTouch Reveal® Plus, powered by Bluestar®, drives evidence-based clinical outcomes.1,2

See What the OneTouch Reveal® Plus Mobile Diabetes Coaching App Can Offer
Woman Looking At Phone

By adding the OneTouch Reveal® Plus app to your portfolio, you're putting data-driven technology to work for your members. The 24/7 digital coaching tool helps people with diabetes build better self-care skills that can result in greater glycemic control to positively impact A1C levels.

OneTouch Reveal® Plus supports key diabetes self-care behaviors identified by the ADA and AADE including:

  • Glucose monitoring and medication alerts
  • Healthy eating and exercise habits
  • Immediate guidance to minimize related risks

    Supportive AI Technology

    The digital coach provides thousands of customized messages, for actionable, real-time guidance.

    Manage Related Conditions

    Features support self-care for hypertension and weight management, two conditions that often affect people with diabetes and lead to compounding care.

    Care Team Support

    The information provided by the SMART Visit Report can enable physicians to make informed prescribing decisions.

    OneTouch Reveal® Plus supports key diabetes self-care behaviors identified by the ADA and AADE including:

    • Glucose monitoring and medication alerts
    • Healthy eating and exercise habits
    • Immediate guidance to minimize related risks
    Supportive AI Technology

    The digital coach provides thousands of customized messages, for actionable, real-time guidance.

    Manage Related Conditions

    Features support self-care for hypertension and weight management, two conditions that often affect people with diabetes and lead to compounding care.

    Care Team Support

    The information provided by the SMART Visit Report can enable physicians to make informed prescribing decisions.

    Studies in Type 2 diabetes

    3-month randomized-controlled clinical trial

    In a prospective, randomized, controlled study, Quinn et al. (Diabetes Technology and Therapeutics, 2008) found that individuals whose A1C levels were greater than or equal to 7.5% within most recent three months and received Welldoc’s software experienced an average decrease in A1C of 2.03%. Patients in the control group obtained an average A1C reduction of 0.68% (P < 0.02, one-tailed). Of the intervention patients, 84% had medications titrated or changed by their HCP compared to controls (23%, P = 0.002).

    Read the abstract here

    12-month randomized-controlled clinical trial

    In a prospective, randomized, controlled study, Quinn et al. (Diabetes Care, 2011) found that, individuals with type 2 diabetes whose A1C levels were poorly controlled (>9.0%) or abnormal (7.5-8.9%) at the time of enrollment, and who were randomized to use a mobile phone app to help them manage their diabetes in addition to usual care, improved A1C by an average 1.9%, compared with 0.7% improvement in persons randomized to usual care alone, a difference of 1.2% (P < 0.001) over 12 months.

    Read the abstract here

    Testing the Relationship Between A1C Reduction and Cost Savings in Type 2 Diabetes

     

    Welldoc funded a retrospective analysis in partnership with IBM Watson Health. They provided IBM Watson Health starting and ending A1C data from 3,000+ of their BlueStar® users. Documented A1C reductions associated with BlueStar® are correlated with cost differences associated with the factors listed below.

    Hospitalizations, ER visits,
    and HCP office visits

    Cost of devices, supplies,
    and medications

    Cost of comorbid complications
    of diabetes

    Where did the data come from?

     

    Claims data from patients in the IBM Watson Health's Market Scan Database, which captures claims data of more than 200 million individuals in the US.

    What did the study find?

     

    Once the patients were stratified by A1C band, the analysis was customized for the commercial sector and the medicare sector.

    Segment by Starting A1C Bands

    For All Bands with A1C
    Medicare Sector
    $ 0
    Commercial Sector
    $ 0
    Estimated cost savings per patient, annually
    Truven MarketScan Database: Annual Cost Per Patient is average amount paid for any healthcare claim within 365 days for: 1) patients with at least two lab results within the same A1C range; and 2) patients with four lab results within the same A1C range. Percentage in Band Today is based on national attrition levels in Truven database.3
    Truven MarketScan Database: Annual Cost Per Patient is average amount paid for any healthcare claim within 365 days for: 1) patients with at least two lab results within the same A1C range; and 2) patients with four lab results within the same A1C range. Percentage in Band Today is based on national attrition levels in Truven database.2
    Icon Doctor

    Clinically Proven
    Outcomes

    More than 40 peer-reviewed posters and publications highlight the value of the OneTouch Reveal® Plus app. Learn more about these publications on Welldoc.

    Icon USD

    Cost-Effective
    Care

    Estimated annual cost savings ranging from $1,824 - $5,244 per user resulting from managing glycemic variability3.

    Icon Checklist

    A Comprehensive
    Solution

    Additional features for blood pressure and weight management help members manage multiple chronic conditions and associated costs.

    Icon Real-Time Guidance

    Real-Time
    Guidance

    The digital solution takes the guesswork out of meter readings with actionable coaching for high and low results.

    OneTouch Verio Flex® Glucose Meter
    Image
    Onetouch® logo
    Image
    Onetouch® logo

     

    A Trusted Leader in Diabetes Care

    Every day around the world, more than 20 million people rely on OneTouch® products, backed by more than 35 years in the business of improving diabetes self-care.

    Icon Device

    Class II Medical
    Device

    OneTouch Reveal® Plus is cleared by the FDA and designated as a Class II Medical Device.

    Icon Lock

    Privacy &
    Digital Security

    OneTouch Reveal® Plus is SOC2 Certified, ISO13485 Certified and HIPAA Compliant.

    Icon Chip

    Proven
    Outcomes

    Evidence-based clinical outcomes3,4. Economic outcome analysis conducted by IBM Watson Health.

    Two easy-to-access options combine the power of the OneTouch Reveal® Plus app with products from our #1 selling brand.

    What does investing in the OneTouch Reveal® Plus app look like?

    Dollar Sign

    Easy Payment
    Options

    We offer pricing options that fit your budget and performance indicator needs.

    Icon Integration

    Flexible
    Implementation

    Our customized activation and engagement support provides seamless integration into your current program.

    Icon Innovation

    Innovation that
    Supports Employees

    We are constantly striving to delight and innovate with enhancements that evolve with your employees' needs.

    Learn More


    Add the OneTouch Reveal® Plus app to your diabetes care portfolio today.

    * required

    The information collected in this form will be treated in accordance with LifeScan’s privacy policy.

    The OneTouch Reveal® Plus app, powered by BlueStar®, is indicated for use by patients aged 18 and older who have Type 1 or Type 2 diabetes and their healthcare providers. The app is not intended to replace the care provided by a licensed healthcare professional. The app should not be used by patients with gestational diabetes or patients using an insulin pump. BlueStar® is a Welldoc, Inc. patented system. The OneTouch Reveal® Plus app is manufactured by Welldoc, Inc.

    1Quinn CC, et al. Diabetes Care. 2011:34:1934-1942.

    2Quinn CC, et al. Diabetes Technol Ther. 2008;10:160-168

    3Market Scan Analysis from Truven Analytics, an IBM Watson Health Company, for data collected between January 01, 2014 and December 31, 2015.

    The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by LifeScan Scotland Ltd. and its affiliates is under license. Other trademarks and trade names are those of their respective owners.

    US-OTRP-2000003